OrbiMed and Morningside Ventures led a €39m Series C round in ENYO Pharma.

OrbiMed, a healthcare-dedicated investment firm, and Morningside Ventures, an investment group, led a €39m Series C round in ENYO Pharma, a clinical-stage biopharmaceutical company, with participation from other existing investors including AndEra Partners, Bpifrance InnoBio and Bpifrance Large Ventures. ” We are delighted with this support from our existing investors. There are huge unmet needs in many kidney diseases with fibrosis or inflammatory components. These patients almost invariably progress to end-stage kidney disease despite current therapies. The results already obtained with Vonafexor, our highly differentiated anti-inflammatory and fibrolytic lead compound, in patients with moderate kidney impairment and in several preclinical protocols, make us confident that it will greatly benefit to those patients with rare kidney diseases like Alport syndrome,“ Jacky Vonderscher, ENYO Pharma CEO.